X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

LEUKEMIA

期刊標題檢索 LEUKEMIA 最新評論: Friends, how long does it take for something to be under consideration... (2024-05-05)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[LEUKEMIA]您好,您是該頁面的第 58202 位訪客。

期刊簡介
期刊名稱LEUKEMIA LEUKEMIA
LetPub Score
9.1
50 ratings
Rate

Reputation
10.0

Influence
8.3

Speed
9.7

期刊簡稱LEUKEMIA
ISSN0887-6924
E-ISSN1476-5551
h-index176
CiteScore
CiteScoreSJRSNIPCiteScore Rank
18.103.6622.441
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Hematology
Q17 / 137
Category: Medicine
Subcategory: Oncology
Q124 / 404
Category: Medicine
Subcategory: Cancer Research
Q117 / 230

自引率 (2023-2024)3.10%自引率趨勢
掲載範囲
Leukemia publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.
Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction, molecular targets for therapy and more.
We publish a range of content types including original research articles, reviews, letters, correspondence and comments that elaborate on significant advances in the field and cover topical issues.
官方網站https://www.nature.com/leu
在線稿件提交https://mts-leu.nature.com/
開放訪問No
出版商Springer Nature
主題領域医学
出版國/地區ENGLAND
發行頻率月刊
創刊年1997
每年文章數186每年文章數趨勢
黃金OA百分比54.56%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
HEMATOLOGYSCIEQ16/97
ONCOLOGYSCIEQ119/322
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0887-6924%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Ordinary, 3-6 Week(s)
競爭力 *來自作者的數據: Very difficult
參考鏈接
相關期刊 【LEUKEMIA】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Journal of Hematology & OncologyH-index: 60

    CiteScore: 48.10
    BLOODH-index: 426

    CiteScore: 23.60
    AMERICAN JOURNAL OF HEMATOLOGYH-index: 92

    CiteScore: 15.70
    HAEMATOLOGICAH-index: 125

    CiteScore: 14.10
    BLOOD REVIEWSH-index: 85

    CiteScore: 13.80
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYH-index: 111

    CiteScore: 11.00
    BRITISH JOURNAL OF HAEMATOLOGYH-index: 172

    CiteScore: 8.60
    SEMINARS IN HEMATOLOGYH-index: 88

    CiteScore: 6.20
    HEMATOLOGICAL ONCOLOGYH-index: 42

    CiteScore: 4.20
    CURRENT OPINION IN HEMATOLOGYH-index: 90

    CiteScore: 6.60
    學科內最受檢索的期刊 頁面查看次數
    BLOOD111052
    Journal of Hematology & Oncology101264
    BRITISH JOURNAL OF HAEMATOLOGY50936
    LEUKEMIA & LYMPHOMA44526
    Hematology37484
    ANNALS OF HEMATOLOGY36120
    AMERICAN JOURNAL OF HEMATOLOGY35412
    LEUKEMIA RESEARCH34144
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY32876
    HAEMATOLOGICA27103
  •  

    LEUKEMIA LEUKEMIA
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [LEUKEMIA] 的評論撰寫評論
作者: 重阳凌文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-05 18:07:01 評論於
Friends, how long does it take for something to be under consideration? I've been waiting for over half a month
(0) 讚! | 重阳凌文

作者: 小美


領域: 医学
審稿時間: 3.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-02 15:58:22 評論於
Friends, how long does "under consideration" usually last, and what stage does it belong to? It has been unchanged for over ten days ?
(0) 讚! | 小美

作者: 宛旋小公主


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-16 12:14:55 評論於
How long did it take for the OP to submit for review?
(0) 讚! | 宛旋小公主

作者: 南川烨霖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-07 10:09:50 評論於
How do you know if you have been rejected? Did you receive an email, or does decision send to reviewers mean rejection?
(0) 讚! | 南川烨霖

作者: 四风如彤


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-03 19:18:08 評論於
I was not asked to redo the experiment by the reviewers, just to revise the written content. The editor rejected it too
(0) 讚! | 四风如彤

作者: 震雷暄妍


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-27 23:09:22 評論於
Review Speed: 12.0 Experience Sharing: Academic editors feel busy and respond slowly
(0) 讚! | 震雷暄妍

作者: 天际桂霞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-26 21:54:23 評論於
I also want to know, does anyone know?
(0) 讚! | 天际桂霞

作者: 天际桂霞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-26 17:14:17 評論於
We think the same
(0) 讚! | 天际桂霞

作者: 天际桂霞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-26 12:07:25 評論於
I also want to know
(0) 讚! | 天际桂霞

作者: 天际桂霞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-26 09:06:34 評論於
May I ask what is the status of the external audit submission? Is it also under consideration?
(0) 讚! | 天际桂霞

作者: 筑阳新春


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-22 12:04:39 評論於
It's a shame that I found out too late, thank you, senior
(0) 讚! | 筑阳新春

作者: 墟散伟博


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-14 19:46:01 評論於
Yes, leukemia tends to be more clinical, but if the mechanism is well studied, it's best to publish in basic journals like NC
(0) 讚! | 墟散伟博

作者: 墟散伟博


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-14 17:55:48 評論於
This means that there are too many images in each small image in your main image, and leikemia magazine is about to be published. The main image is too large to affect the layout space, so you need to transfer a large number of small images from the main image to the supplementary image
(0) 讚! | 墟散伟博

作者: 活人幼珊


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-16 14:48:03 評論於
Could you please provide the submission process for the difficult magazine?
(0) 讚! | 活人幼珊

作者: 碧水采香


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-16 08:43:59 評論於
Hello, do you know what this means? How many pictures do we need after all?
(0) 讚! | 碧水采香

作者: 风啸俊衡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-05-14 12:41:20 評論於
I am also a reviewer and my opinions can completely resolve the issue, but they were rejected by the editor
(0) 讚! | 风啸俊衡

作者: 风啸俊衡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-05-13 22:33:28 評論於
Review speed: 4.0
Emphasis on research direction: mechanism; 
Leukemia drug experience sharing: The review took three months, with two reviewers suggesting major revisions. The editor rejected the paper directly. It seems they value functionality more than mechanism
(0) 讚! | 风啸俊衡

作者: 筑阳新春


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-24 11:22:59 評論於
The editor sent an email saying that figures are heavily overloaded, each figure with more than 3 subfigures count twice. Does anyone know what this means?
(0) 讚! | 筑阳新春

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-10 19:23:04 評論於
Field to be filled
(0) 讚! | 法慧和同

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-10 18:10:50 評論於
The associate editor should directly reject this
(0) 讚! | 法慧和同

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-10 18:10:17 評論於
Research Proposal
(0) 讚! | 法慧和同

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-10 17:15:41 評論於
Just wait a few more days
(0) 讚! | 法慧和同

作者: Zora Taylor


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-10 08:45:53 評論於
Got rejected, sad
(0) 讚! | Zora Taylor

作者: Zora Taylor


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-05 16:16:06 評論於
A few days ago it was just submitted, and yesterday the status changed to "decision sent to reviewers." Does this mean it's being sent for external review? How strange. And it changed from "live manuscript" to "post decision." The author also didn't receive a rejection email. Has anyone else experienced a similar situation?
(0) 讚! | Zora Taylor

作者: 月河寻安


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-01 12:01:33 評論於
Yes, who the editor is matters a lot. The questions raised by the reviewers are not negative, but they still rejected it. Maybe it was just bad luck
(0) 讚! | 月河寻安

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [LEUKEMIA] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*